Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing liquid biopsies into clinical decision making for cancer immunotherapy.
Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B. Quandt D, et al. Among authors: cannarile m. Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Oncotarget. 2017. PMID: 28501851 Free PMC article. Review.
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. Menke-van der Houven van Oordt CW, et al. Among authors: cannarile ma. Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098. Oncotarget. 2016. PMID: 27507056 Free PMC article. Clinical Trial.
Systematic evaluation of immune regulation and modulation.
Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B. Stroncek DF, et al. J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. J Immunother Cancer. 2017. PMID: 28331613 Free PMC article. Review.
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges.
Cesano A, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Thorsson V, Tschernia N, Wang E, Wells DK, Wyant TL, Rutella S. Cesano A, et al. Among authors: cannarile ma. J Immunother Cancer. 2020 Dec;8(2):e001472. doi: 10.1136/jitc-2020-001472. J Immunother Cancer. 2020. PMID: 33323463 Free PMC article.
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges.
Rutella S, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Thorsson V, Tschernia N, Wang E, Wells DK, Wyant TL, Cesano A. Rutella S, et al. Among authors: cannarile ma. J Immunother Cancer. 2020 Oct;8(2):e001389. doi: 10.1136/jitc-2020-001389. J Immunother Cancer. 2020. PMID: 33127656 Free PMC article.
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.
Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH. Pradel LP, et al. Mol Cancer Ther. 2016 Dec;15(12):3077-3086. doi: 10.1158/1535-7163.MCT-16-0157. Epub 2016 Aug 31. Mol Cancer Ther. 2016. PMID: 27582524
30 results